The FDA Approves the First Pulmonary Valve Built to Grow With a Child
The Autus Size-Adjustable Valve can be widened by balloon catheter as a child grows, and it is the first valve approved in the U.S. with polymer leaflets. The goal is fewer open-heart operations, though the long-term data are still coming.
For children with congenital pulmonary valve disease, the timing of valve replacement has always involved a trade-off. Replace too late and the right heart suffers. Replace too early and the child outgrows the valve and goes back to the operating room, sometimes more than once. A device approved by the FDA on Oct. 1 is designed to soften that trade-off.
The FDA approved the Autus Size-Adjustable Valve, a surgically implanted pulmonary valve for pediatric patients. It is the first heart valve designed to be expanded after surgery to keep pace with a child's growth, and the first valve approved in the U.S. to use polymeric material rather than animal tissue for its leaflets. Edwards Lifesciences received the approval for the device, which was developed by Autus Valve Technologies.
How it works
The valve can be implanted as small as about 13 millimeters in diameter, a size suited to a toddler or preschool child, and later widened with a balloon catheter as the child grows, up to 22 millimeters, comparable to an adult pulmonary valve. The FDA noted that traditional animal-derived leaflets tend to harden and break down faster in children, often leading to earlier repeat surgery, and that one-year follow-up data suggest the synthetic leaflets hold up well over time. This is the first time the agency has approved a valve with polymeric leaflets for any indication.
Pulmonary valve atresia and stenosis together affect about 4,200 babies in the United States each year, according to the Centers for Disease Control and Prevention figures the FDA cited.
What the data show, and what they do not
The approval is based on a clinical study that enrolled 62 pediatric patients at 12 U.S. sites. At six months, the first 60 patients showed acceptable hemodynamic performance, with no more than mild regurgitation. All procedures were successful, with no deaths, strokes, or clots requiring additional treatment.
Two patients in the study have had their valves expanded. The FDA itself calls that experience limited.
The FDA was direct about the open questions. Three patients had a fracture of the valve frame and two had reduced movement of one leaflet, none of which caused symptoms. Valve performance began to deteriorate in two patients who started to outgrow the valve, and both were expanded successfully without surgery, but the agency described that experience as limited. Longer-term studies are under way to understand those risks and to show whether expansion can keep the valve working and reduce the number of operations.
The regulatory path
The device went through premarket approval, the FDA's most stringent pathway for high-risk Class III devices. It had Breakthrough Device designation and is the first pediatric approval to come out of the FDA's Total Product Life Cycle Advisory Program, a voluntary program meant to speed development of high-quality devices.
"The Autus Size-Adjustable Valve gives doctors the option of far fewer trips to the operating room, which may result in better quality of life for these children and their families," said Michelle Tarver, MD, PhD, director of the FDA's Center for Devices and Radiological Health.
For pediatricians and family physicians who follow these children between cardiology visits, the practical message is modest for now. The device is new, the expansion experience is small, and decisions about it will sit with congenital heart teams. But families will hear about it, and it helps to know both the promise and the limits the FDA itself described.
Dr. Reyes practices emergency medicine and writes about clinical decision making under pressure and the technology entering the ED.
This article is for professional education and does not replace clinical judgment. Treatment decisions should be based on the individual patient and current guidelines.
